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Purpose: Substance use is linked with poor outcomes among people
living with HIV (PLWH) and is associated with mental health disorders.
This analysis examines the impact of decreasing substance use, even
without abstinence, on depressive symptoms among PLWH.
Methods: Data are from PLWH enrolled in the Centers for AIDS
Research Network of Integrated Clinical Sites cohort. Participants
completed longitudinal assessments of substance use (modified
ASSIST) and depressive symptoms (PHQ-9). Changes in substance
use frequency were categorized as abstinence, reduced use, and
nondecreasing use. Adjusted linear mixed models with time-updated
change in substance use frequency and depressive symptom scores
were used to examine associations between changes in the use of
individual substances and depressive symptoms. Analyses were
repeated using joint longitudinal survival models to examine
associations with a high (PHQ-9 $10) score.
Results: Among 9905 PLWH, 728 used cocaine/crack, 1016 used
amphetamine-type substances (ATS), 290 used illicit opiates, and
3277 used marijuana at baseline. Changes in ATS use were
associated with the greatest improvements in depressive symptoms:
stopping ATS led to a mean decrease of PHQ-9 by 2.2 points (95%
CI: 1.8 to 2.7) and a 61% lower odds of PHQ-9 score $10 (95% CI:
0.30 to 0.52), and decreasing ATS use led to a mean decrease of 1.7
points (95% CI: 1.2 to 2.3) and a 62% lower odds of PHQ-9 score
$10 (95% CI: 0.25 to 0.56). Stopping and reducing marijuana and
stopping cocaine/crack use were also associated with improvement
in depressive symptoms.
Conclusions: We demonstrated that both substance use reduction
and abstinence are associated with improvements in depressive
symptoms over time.
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INTRODUCTION
Substance use is a public health challenge in the United
States among many different vulnerable populations. Sub-
stance use is associated with a range of comorbidities among
people living with HIV (PLWH), including viral hepatitis,
tuberculosis, bacterial infections, kidney disease, atheroscle-
rosis, cancer, and mental health disorders.1
In particular, current substance use is associated with
increased rates of depressive symptoms and depression
among PLWH.2–7 Managing mental health disorders is
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challenging and, if untreated, the mental health disease will 
negatively impact HIV care along the HIV care continuum, 
including delayed linkage to care, delayed initiation of 
antiretroviral therapy, suboptimal medication adherence, and 
worse clinical outcomes.3 Achieving abstinence in PLWH 
with substance use disorders is challenging,1 often requiring 
multifaceted and interdisciplinary approaches. Addressing 
substance use, however, is a key intervention for improving 
depressive symptoms in PLWH, especially because 
these conditions often co-occur and impact the HIV care 
continuum.1–7
We hypothesized that a reduction in substance use may 
have benefits in terms of depressive symptoms, even if 
abstinence is not achieved. Substance use can be considered 
a process of negative reinforcement, due to a decrease in the 
function of normal reward-related neurocircuitry, which 
results in increased depressive symptoms among users.8 
Previous studies, however, have predominantly focused on 
achieving complete abstinence, which is often the main goal 
of substance use treatment. Harm reduction, the reduction in 
drug use, remains an important goal, but it is crucial to 
determine whether such reductions have resultant improve-
ments in health, including depression outcomes. Our objec-
tive was to evaluate the impact on depressive symptoms of 
reducing substance use, with or without achieving abstinence. 
We considered this question in PLWH enrolled in the Centers 
for AIDS Research Network of Integrated Clinical Systems 
(CNICS) cohort.9
METHODS
This study includes PLWH aged 18 years or older and 
enrolled at 1 of 6 CNICS sites (Johns Hopkins University; 
University of Alabama at Birmingham; University of 
California, San Diego; University of California, San Francisco; 
University of North Carolina at Chapel Hill; and University of 
Washington, Seattle). CNICS is a longitudinal observational 
study of PLWH receiving primary care at CNICS sites from 
January 1, 1995, to the present.9 In total, 9905 participants were 
eligible for inclusion in analyses.
All participants completed longitudinal assessments of 
substance use frequency including cocaine/crack; 
amphetamine-type substances (ATS) that included metham-
phetamines; illicit opioids; and marijuana. Participants had 
to have 2 or more substance use assessments during cohort 
follow-up to be eligible for this study. We formed sub-
cohorts of participants who were using a specific substance  
to ensure measurement of reduced use or abstinence were 
performed among participants eligible to reduce use due to 
current use.
As a sensitivity analysis, to enrich the number of 
opioid users, we also pooled CNICS with Project STRIDE10 
from the Seek, Test, Treat, and Retain cohort.10 Project 
STRIDE is a randomized controlled trial of PLWH with 
substance use disorders that includes a buprenorphine plus 
naloxone (BPN) intervention, is registered at www. 
clinicaltrials.gov (NCT 01550341), and has similar meas-
ures of depressive symptoms and substance use (making it 
ideal for pooling).
Substance Use
In the CNICS cohort, PLWH completed an approxi-
mately 10-minute clinical assessment with touchscreen tab-
lets, with a planned frequency of every ;6 months, as part of 
routine clinical care.11 The CNICS clinical assessment 
includes measures of substance use (modified Alcohol, 
Smoking, and Substance Involvement Screening Test)12 as 
well as a broad group of other patient-reported measures and 
outcomes (including alcohol use). Assessments of substance 
use included a Likert scale for frequency of use in the past 
30 days.
We categorized frequency of use into less than weekly, 
1–3 times per week, and daily or almost daily, based on 
participant responses to the study instruments. Changes in 
substance use frequency were defined as a change from one 
category to another. Possible changes included abstinence 
(change to no use), reduced use (change to a lower frequency 
category), and nondecreasing or increasing use (the same or 
higher category of use, as compared to baseline).
Depressive Symptoms
Depressive symptom scores were assessed using the 
Patient Health Questionnaire (PHQ)-9. CNICS administered 
the PHQ-9 to participants repeatedly over follow-up, through 
a Computer-Assisted Self-Interview (CASI) system. The 
PHQ-9 has been validated as a scale for detecting depressive 
symptoms both in outpatient populations13 and in diverse/
international populations.14 It has high screening utility and is 
used in clinical care to screen for depression among 
PLWH.15,16
Statistical Models
Linear mixed models with time-updated change in 
substance use frequency and depressive symptom scores 
were used to examine associations between changes in the 
use of individual substances and depressive symptoms. For 
each substance, a specific cohort was formed of participants 
who were users at study baseline. These models were adjusted 
for other substance use, with random slopes and intercepts at 
the participant level to handle repeated measures over follow-
up of both substance use and depressive symptoms. This type 
of mixed-model approach to link changes in drug exposure 
levels to changes in continuous outcomes has been used in 
pharmacoepidemiology contexts17 and is a well-known 
approach to handle irregular data collection and participants 
lost to follow-up.18,19 All estimates were adjusted for age, 
sex, use of other substances, alcohol use, and calendar year.
We were also interested in whether findings were the 
same if the outcome of interest was screening positive for 
depression rather than change in depression symptom score as 
a continuous variable. Therefore, we dichotomized depression 
scores using a cutoff point of $10 (high PHQ-9) to indicate 
high predictive value for screening positive for depression20 
and repeated analyses using a joint longitudinal and survival 
model21 to examine the impact of decreasing drug use and of 
abstinence for each drug due to known limitations with less 
complex models.22
We also considered the possibility of a bidirectional
association. We examined change in days of substance use
among participants experiencing a drop in PHQ-9 score over
follow-up, using a linear mixed-model approach. All statis-
tical analysis was performed in STATA 14 (StataCorp, 2017,
Stata Statistical Software: Release 15, College Station, TX:
StataCorp LLC).
RESULTS
CNICS enrolled patients in clinical care, resulting in
a large diverse cohort. Among 9905 PLWH, the mean age
was 44 years, 16% of participants were female, and 40% used
a substance at baseline (Table 1). Overall, 728 participants
reported cocaine/crack use, 1016 ATS use, 290 illicit opioid
use, and 3277 reported marijuana use at baseline.
Changes in ATS use were associated with the greatest
improvements in depressive symptoms. Abstinence from
ATS was associated with a mean difference in the depressive
symptom score of Δ 22.2 PHQ-9 points [95% confidence
interval (CI):22.7 to21.8] or a 61% lower odds of screening
positive for depression (95% CI: 0.30 to 0.52) compared with
those who continued their ATS use without a decrease in
frequency. Decreasing ATS without abstinence was associ-
ated with a mean difference of Δ 21.7 PHQ-9 points (95%
CI: 22.3 to 21.2) or 62% lower odds of screening positive
for depression (95% CI: 0.25 to 0.56) compared with those
who did not decrease their use (Table 2).
Decrease in use of other substances had more modest
associations with depressive symptoms. Stopping marijuana
was associated with a mean decrease in the depressive
symptom score of Δ 20.5 PHQ-9 points (95% CI: 20.7 to
20.3) or 28% lower odds of screening positive for depression
(95% CI: 0.58 to 0.88), and decreasing marijuana use was
associated with a mean decrease of Δ 20.4 PHQ-9 points
(95% CI: 20.7 to 20.1) or 30% lower odds of screening
positive for depression (95% CI: 0.59 to 0.84). Stopping
cocaine/crack was associated with a mean difference in the
PHQ-9 score of Δ 20.8 points (95% CI: 21.3 to 20.4) or
24% lower odds of screening positive for depression (95%
CI: 0.56 to 1.03); however, decreasing cocaine/crack use
without abstinence was not associated with a significant
change in PHQ-9 score or the odds of screening positive for
depression [ΔPHQ-9 score = 20.5 points/odds ratio (OR) =
0.97]. Finally, neither stopping or reducing use of opiates
over follow-up was associated with a significant reduction of
depressive symptom (ΔPHQ-9 score = 20.6 points/OR =
0.79 and ΔPHQ-9 score = 20.5/OR = 1.20, respectively)
(Table 2). Results for opioid use were similar to the CNICS-
only results (Table 2) when we included an additional study,
Project STRIDE, with a high-level of opioid use to improve
precision on the illicit opioid estimates (Table 1, Supplemen-
tal Digital Content, http://links.lww.com/QAI/B196).
Looking for a bidirectional association, we considered the
association between reducing PHQ-9 score over follow-up and
frequency of substance use. There was an association for cocaine/
crack (Δdays of cocaine/crack use 20.07; 95% CI: 20.12 to
20.02), ATS (Δdays of ATS use 20.21; 95% CI: 20.30
to 20.13), and marijuana (Δdays of marijuana use 20.25; 95%
CI: 20.44 to 20.06) but not for opiates (Δdays of opiate use
20.03; 95% CI: 20.08 to 0.02) (Table 2, Supplemental Digital
Content, http://links.lww.com/QAI/B196, individual logistic and
survival models, by substance, are Tables 3–10, Supplemental
Digital Content, http://links.lww.com/QAI/B196).
DISCUSSION
We demonstrated that both substance use reduction and
abstinence are associated with improvements in depressive
symptoms over longitudinal follow-up in PLWH. Relative to
other substances, reducing ATS use was more strongly
associated with alleviation of depressive symptoms, perhaps
suggesting that it has greater detrimental clinical impact,
including on depression, than other drugs in this population.
Our results showing that cessation of substance use is
associated with improved depression scores are not surpris-
ing, although it was reassuring to see the level of concrete
improvement in routine care environments. It is well known
that depression is associated with substance use.23–25 There is
also evidence that substance use may interfere with pharma-
cologic treatment for depression in PLWH, resulting in less
benefit of depression treatment in randomized trials,26
although there may be less impact for cognitive–behavioral
therapy.27,28
Treatment for depression in PLWH is important because
depression is a known barrier to HIV medication adherence29,30
and a source of morbidity and mortality in its own right.31,32
Substance use interferes with improving depression and should
be addressed as a part of any treatment plan. Our results should
provide additional support for studying interventions that lead to
TABLE 1. Demographic and Clinical Characteristics for 9905
People Living With HIV From the CNICS Cohort, Including
Days of Use Scaled to a 30-Day Period
CNICS







Current use of cocaine/crack 7%
Mean days of cocaine/crack use (among users) 3 (7)
Current use of ATS 10%
Mean days of ATS (among users) 6 (11)
Current illicit opiate use 3%
Mean days of illicit opiate use (among users) 6 (11)
Current marijuana use 33%
Mean days of marijuana use (among users) 12 (14)
Current alcohol use 67%
Mean days of alcohol use (among users) 5 (6)
Current binge alcohol use 34%
Mean days of binge alcohol use (among users) 2 (6)
Depression (PHQ-9 score) 6 (6)
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